Trial Profile
Phase II Study of Lenalidomide Plus Rituximab in Patients With Previously Untreated Mantle Cell Lymphoma
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 11 Sep 2023
Price :
$35
*
At a glance
- Drugs Lenalidomide (Primary) ; Rituximab (Primary)
- Indications Carcinoma; Mantle-cell lymphoma; Non-Hodgkin's lymphoma
- Focus Therapeutic Use
- 24 Aug 2023 Status changed from active, no longer recruiting to completed.
- 31 Jan 2023 Planned End Date changed from 1 Oct 2022 to 30 Jun 2023.
- 08 Dec 2020 Results of 7 year follow up analysis presented at the 62nd Annual Meeting and Exposition of the American Society of Hematology